Cell Medica and Baylor extend partnership for off-the-shelf T Cells

By Staff Reporter

- Last updated on GMT

Related tags: Medicine

Baylor University, texas c 1892 - Image: Wikimedia/A. L. Westyard
Baylor University, texas c 1892 - Image: Wikimedia/A. L. Westyard
Baylor College of Medicine has extended a partnership to develop off-the-shelf allogeneic cell therapies for Cell Medica.

The co-development agreement sees the Houston, Texas-based Baylor College of Medicine perform the research required to develop off-the-shelf natural killer T (NKT) cell therapies with UK biotech Cell Medica funding the project.

“This particular off-the-shelf project is in the pre-clinical research stages,”​ a Cell Medica spokesperson told Biopharma-Reporter.com. “It has emerged from the collaboration that Cell Medica and Baylor started in June this year.”

The allogeneic NKT cells are being developed to be used to treat multiple cancer patients and the collaboration is looking to avoid the risk of graft versus host disease (GvHD) – a side effect where the patient rejects the therapy due to the many donor nature of off-the-shelf T Cell therapies.

“It is likely the early Phase 1/2 trials will be conducted at Baylor College of Medicine in Houston [and while] the long-term commercial manufacturing strategy for this product has not been decided, but Cell Medica’s future aim is to have a commercial cell factory for every key market -  Europe, Americas, and Asia,” ​we were told.

Manufacturing would involve large scale cell culturing, the spokesperson continued, with commercial production likely to be moved to bioreactors which can be made to order to suit different production volumes.

“The starting material will be a blood sample or apheresis from healthy donors. NKT cells grow very well in culture which is an advantage when considering large scale production runs.”

Financial details were not divulged.

Related news

Show more

Related products

show more

Liposomal and Nanoparticle Technology

Liposomal and Nanoparticle Technology

Pfizer CentreOne | 18-Nov-2022 | Technical / White Paper

Medical science is continuously searching for better ways to administer drugs into the body and to maximize the therapeutic effectiveness of the drugs...

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

Scalability, Quality, and Speed with Transposons

Scalability, Quality, and Speed with Transposons

Wheeler Bio | 20-Oct-2022 | Technical / White Paper

To solve for the significant bottlenecks often presented by conventional cell line development processes, this article discusses how Wheeler Bio is leveraging...

Accelerating Time to IND with Pharma 4.0

Accelerating Time to IND with Pharma 4.0

Wheeler Bio | 22-Sep-2022 | Technical / White Paper

The future of the biopharmaceutical industry hinges on its adoption of 21st-century digital tools and automation.

Related suppliers

Follow us


View more